Oman Pharmaceuticals & Healthcare Report

Published 22 June 2015

  • 113 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Oman Pharmaceuticals & Healthcare Report

BMI View: Growth in Oman's pharmaceutical and healthcare market s will be driven by the roll out of medical insurance schemes and the completion of two medical cities , capitalising on the increased demand for healthcare services in both the domestic and international markets. Both projects are valued at over USD1bn each and will significantly improve the level of healthcare provision in Oman.

Headline Expenditure Projections

  • Pharmaceuticals: OMR203mn (USD528mn) in 2014 to OMR217mn (USD564mn) in 2015; 6.8% in local currency and US dollar terms. Forecast broadly in line with Q 2 15.

  • Healthcare: OMR853mn (USD2.22bn) in 2014 to OMR939mn (USD2.44bn) in 2015; +10.1% in local currency and US dollar terms. Forecast downgraded slightly from Q215.

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q315, Oman scores 49.0 out of 100 in the BMI Pharmaceutical Risk/Reward Index, which has seen the country maintain its position in 10th place in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

  • Data from the insurance sector in June 2015 indicated that claims paid by companies rose during Q115 by 36% to reach OMR39mn (USD101mn). Health insurance accounted for 22% of total direct premiums.

  • The Ministry of Health launched the National Electronic Health Record System in May 2015. The system links a patient's files in affiliated health institutions so the patient can access their medical history at anytime from anywhere.

  • Two paediatric drugs Advil and Panadol (marketed by GlaxoSmithKline) were recalled by the Ministry of Health in May 2015 due to errors in the dosage advice in their leaflets.

BMI Economic View

The pace of Omani economic activity will slow over 2015, as the continued slump in oil prices weakens business and...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2011-2019)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
23
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
25
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2011-2019)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Oman 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2013-2019)
30
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Economic Analysis
34
Table: OMAN - SELECTED INFRASTRUCTURE AND INDUSTRIAL PROJECTS
39
Industry Risk Reward Indicies
40
Middle East And Africa Risk/Reward Index
40
Oman Risk/Reward Index
48
Rewards
48
Risks
49
Market Overview
50
Industry Trends And Developments
51
Industry Trends And Developments
51
Epidemiology
51
Communicable Diseases
51
Non-Communicable Diseases
53
Healthcare Sector
54
Public Healthcare Sector Developments
56
Private Healthcare Sector Developments
58
Table: Number Of Health Centres In Oman By Region In 2013
61
Table: Number And Type Of Health Institutions In Oman In 2013
61
Healthcare Insurance
62
Telemedicine
64
Medical Tourism
64
Research And Development
66
Clinical Trials
67
Table: Clinical Trials In Oman
68
Regulatory Development
69
Regulatory Developments
70
Intellectual Property Regime
70
Regional Harmonisation
71
Pricing And Reimbursement Regime
72
Competitive Landscape
76
Domestic Pharmaceutical Industry
76
Foreign Pharmaceutical Industry
77
Pharmaceutical Distribution
79
Company Profile
80
Zynova/Oman Pharmaceutical Products Company
80
National Pharmaceutical Industries (NPI)
83
Novartis
86
GlaxoSmithKline
89
Sanofi
91
Johnson & Johnson
93
Demographic Forecast
95
Table: Population Headline Indicators (Oman 1990-2025)
96
Table: Key Population Ratios (Oman 1990-2025)
96
Table: Urban/Rural Population & Life Expectancy (Oman 1990-2025)
97
Table: Population By Age Group (Oman 1990-2025)
97
Table: Population By Age Group % (Oman 1990-2025)
98
Glossary
100
Methodology
102
Pharmaceutical Expenditure Forecast Model
102
Healthcare Expenditure Forecast Model
102
Notes On Methodology
103
Risk/Reward Index Methodology
104
Index Overview
105
Table: Pharmaceutical Risk/Reward Index Indicators
105
Indicator Weightings
106

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc